Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors.

Molpus KL, Redlin-Frazier S, Reed G, Burnett LS, Jones HW
Eur J Gynaecol Oncol. 1998 19 (6): 541-6

PMID: 10215437

PURPOSE OF INVESTIGATION - To review our management experience with uterine mixed mullerian tumors (MMTs) in order to evaluate potential prognostic indicators, and assess the efficacy of various treatment modalities.

METHODS - A retrospective, clinicopathologic evaluation of 43 patients presenting for treatment of uterine MMTs between 1982 and 1992 was conducted. Diagnostic criteria for inclusion was the presence of both a malignant glandular or squamous epithelial component, and a homologous or heterologous stromal component.

RESULTS - Overall 2- and 5-year cancer related Kaplan-Meier survival estimates with 95% confidence intervals were 44 (.28, .59) and 26% [.12, .39], respectively. Survivals were 83 [.62, .99] and 58% [.31, .85] when disease was confined to the uterus, and 22 [.03, .41] and 7% [.01, .20] when disease extended beyond the uterus. Clinical staging was often inaccurate, with 29% of clinical stage I or II disease being upstaged at laparotomy. A significant survival advantage was found in patients with stage I or II disease treated with surgery plus pelvic irradiation (p = 0.001), as compared to those treated with surgery alone. The prognosis after disease recurrence was poor, irrespective of secondary therapy, with a median survival of 11 months.

CONCLUSIONS - A therapeutic advantage may be gained from postoperative pelvic irradiation in the treatment of surgical stage I or II uterine MMT.

MeSH Terms (17)

Adult Aged Aged, 80 and over Confidence Intervals Disease-Free Survival Female Humans Laparotomy Middle Aged Mixed Tumor, Mullerian Neoplasm Staging Pelvis Prognosis Radiotherapy, Adjuvant Retrospective Studies Survival Rate Uterine Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities:

Links